AbbVie’s Parkinson’s disease (PD) therapy has been approved by the US Food and Drug Administration (FDA) to treat motor ...

AstraZeneca (AZ) has received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) for the use of ...

We are proud to announce that AMICULUM has achieved the silver award from EcoVadis, a global leader in sustainability ...

Amgen has shared positive top-line results from a late-stage trial of its B cell-depleting therapy Uplizna (inebilizumab-cdon ...

Inizio Medical has announced the appointment of Matt Wadyka as president, US medical affairs. In this newly created role, ...

AstraZeneca (AZ) has entered into an exclusive licence agreement worth over $1.9bn to advance CSPC Pharmaceutical Group’s pre-clinical lipid-lowering therapy, strengthening the Anglo-Swedish drugmaker ...

Merck & Co – known as MSD outside the US and Canada – has shared positive results from a late-stage study of its anti-PD-1 therapy in head and neck cancer. The phase 3 KEYNOTE-689 trial has been ...

Eli Lilly has partnered with insitro to advance new treatments for metabolic diseases, including metabolic dysfunction-associated steatotic liver disease (MASLD). The new drugs developed under the ...

Ipsen’s Iqirvo (elafibranor) has been approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA) to treat adults with primary biliary cholangitis (PBC). The oral peroxisome ...

AbbVie has shared positive top-line results from a late-stage study of its investigational Parkinson’s disease (PD) drug in adults. The phase 3 TEMPO-1 trial evaluated two fixed doses of the D1/D5 ...

Merck & Co’s – known as MSD outside the US and Canada – Keytruda (pembrolizumab) and Astellas/Pfizer’s Padcev (enfortumab vedotin) have been approved by the Medicines and Healthcare products ...

Researchers from the Institute of Cancer Research (ICR) have highlighted the potential benefits of treating bladder cancer with personalised radiotherapy. More than 130,000 patients are treated on the ...